Company Overview of Valor Biotherapeutics, LLC
Valor Biotherapeutics, LLC engages in the clinical development and commercialization of monoclonal antibody-based therapeutics to treat cancer. Its products include IGN002 that includes an anti-CD20 monoclonal antibody attached to IFN through stable peptide linker system; IGN001 that comprises an anti-Her2 monoclonal antibody attached to IFN through stable peptide linker system; and IGN003 that includes a monoclonal antibody directed towards a validated multiple myeloma target attached to IFN through stable peptide linker system. The company was founded in 2012 and is based in Bryan, Texas.
8800 HSC Parkway
Bryan, TX 77807
Founded in 2012
Key Executives for Valor Biotherapeutics, LLC
Valor Biotherapeutics, LLC does not have any Key Executives recorded.
Valor Biotherapeutics, LLC Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Valor Biotherapeutics, LLC, please visit www.valorbiotherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.